Cost, timeline: Facts about Pfizer-BioNTech's '90% effective' Covid vaccine

U.S. drugmaker Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.

The companies said the vaccine was more than 90% effective and they have so far found no serious safety concerns, priming it for possible speedy regulatory approvals.

Pfizer expects to seek broad U.S. emergency use authorisation in the U.S. of the vaccine for people aged 16 to 85 in coming weeks.

To do so, it will need to have collected two months of safety follow-up data on around half of the study's roughly 44,000 participants, expected in